Screening for Reduced Ovarian Reserve in High-Risk Groups

Abstract

Reduced ovarian reserve (ROR) is a critical determinant of female reproductive potential, particularly in women seeking fertility. High-risk populations including those with genetic predispositions, prior ovarian surgery, chemotherapy exposure, or autoimmune conditions require tailored screening strategies to facilitate early intervention. This review synthesizes current evidence and guidelines on the epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic approaches, management, and emerging therapies for ROR in high-risk cohorts. Emphasis is placed on integrating recent PubMed-indexed data and expert recommendations to optimize clinical outcomes.

Introduction

Ovarian reserve refers to the quantity and quality of oocytes present in the ovaries at any given time, which declines progressively with age and is influenced by genetic and environmental factors. Reduced ovarian reserve, defined by diminished reproductive potential and response to ovarian stimulation, presents a significant challenge in reproductive medicine. Early identification of ROR is particularly crucial in high-risk groups, where the window for intervention may be narrow. This article reviews contemporary approaches to screening, diagnosis, and management of ROR with a focus on evidence-based, guideline-driven strategies for high-risk women.

Epidemiology / Disease Burden

ROR affects approximately 10% of women of reproductive age, with higher prevalence observed in specific high-risk groups. Epidemiological studies reveal increased rates of ROR among women with a family history of premature ovarian insufficiency (POI), those undergoing gonadotoxic treatments, and individuals with autoimmune or genetic disorders. Population-based data underscore the importance of systematic screening, as delayed recognition contributes to infertility, psychosocial distress, and reduced effectiveness of assisted reproductive technologies.

Pathophysiology

The pathophysiology of ROR involves accelerated depletion or dysfunction of the primordial follicle pool. Mechanisms include genetically mediated follicular atresia, direct ovarian injury from toxins or surgery, autoimmunity against ovarian antigens, and chronic inflammatory states. In high-risk groups, such as BRCA mutation carriers or survivors of childhood cancer, both intrinsic and extrinsic factors synergistically impair folliculogenesis, leading to premature depletion of oocytes. Understanding these mechanisms is vital for risk stratification and targeted screening.

Risk Factors

High-risk groups for ROR include women with:

• Family history of early menopause or POI
• Genetic mutations (e.g., FMR1 premutation, BRCA1/2)
• Previous ovarian surgery (e.g., cystectomy, endometrioma excision)
• History of chemotherapy or pelvic radiotherapy
• Endometriosis
• Autoimmune conditions (e.g., thyroiditis, lupus)
• Smoking and environmental toxin exposure

Clinical risk assessment should incorporate detailed personal and family histories, prior medical interventions, and exposure to known ovarian toxins.

Clinical Features

ROR is frequently asymptomatic until reproductive challenges arise. Clinical manifestations may include shortened menstrual cycles, oligomenorrhea, or amenorrhea. In the context of fertility treatment, women with ROR often demonstrate poor ovarian response to gonadotropins and low oocyte yield during assisted reproductive cycles. Subtle endocrine changes, such as elevated follicle-stimulating hormone (FSH) or reduced anti-Müllerian hormone (AMH), may precede overt symptoms.

Diagnosis

Screening for ROR in high-risk groups relies on a combination of biochemical and ultrasonographic markers. Key diagnostic tools include:

• AMH assay: Reflects the size of the antral follicle pool; low values indicate diminished reserve.
• Antral follicle count (AFC): Transvaginal ultrasound quantification of small follicles; AFC <5-7 per ovary suggests ROR.
• Early follicular phase FSH and estradiol: Elevated FSH (>10 IU/L) and estradiol (>60-80 pg/mL) are associated with reduced reserve.

Emerging biomarkers, such as inhibin B and ovarian volume assessment, may offer additional prognostic value. Screening intervals and modalities should be individualized based on risk profile and reproductive planning.

Treatment & Management

Management of ROR in high-risk women is multifaceted, encompassing fertility preservation, individualized reproductive counseling, and, where appropriate, assisted reproductive technologies (ART). Options include:

• Oocyte or embryo cryopreservation prior to gonadotoxic therapies
• Use of donor oocytes in cases of severe depletion
• Optimization of ART protocols (e.g., minimal stimulation, dual stimulation cycles)
• Adjunctive therapies (DHEA, coenzyme Q10) under investigation

Multidisciplinary care involving reproductive endocrinologists, oncologists, and genetic counselors is essential for comprehensive management.

Recent Advances / Emerging Therapies

Recent research has focused on novel biomarkers (e.g., microRNAs, exosomal proteins) to enhance early detection of ROR, particularly in genetically predisposed or iatrogenic cases. Advances in ovarian tissue cryopreservation and transplantation have expanded fertility preservation options for prepubertal girls and those unable to undergo conventional stimulation. Investigational therapies targeting ovarian stem cells and in vitro activation of dormant follicles hold promise but require further clinical validation.

Guideline Recommendations

Professional societies, including the American Society for Reproductive Medicine (ASRM) and European Society of Human Reproduction and Embryology (ESHRE), recommend proactive screening for ROR in high-risk populations. Guidelines emphasize informed consent, shared decision-making, and individualized assessment of the benefits, limitations, and psychosocial implications of screening and fertility preservation. Regular updates to protocols are warranted as new evidence emerges.

Conclusion

Early and accurate screening for reduced ovarian reserve in high-risk groups is essential for optimizing reproductive outcomes and psychological well-being. A nuanced understanding of epidemiology, risk factors, and pathophysiology informs evidence-based screening and management. Recent advances in diagnostic and fertility preservation technologies, guided by evolving clinical guidelines, offer new hope for women at increased risk for ROR. Ongoing research and multidisciplinary collaboration will further refine strategies to address this complex reproductive challenge.